BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 26186715)

  • 1. Human Onchocerciasis: Modelling the Potential Long-term Consequences of a Vaccination Programme.
    Turner HC; Walker M; Lustigman S; Taylor DW; Basáñez MG
    PLoS Negl Trop Dis; 2015; 9(7):e0003938. PubMed ID: 26186715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa.
    Wanji S; Chounna Ndongmo WP; Fombad FF; Kengne-Ouafo JA; Njouendou AJ; Longang Tchounkeu YF; Koudou B; Bockarie M; Fobi G; Roungou JB; Enyong PA
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006750. PubMed ID: 30226900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.
    Gardon J; Gardon-Wendel N; Demanga-Ngangue ; Kamgno J; Chippaux JP; Boussinesq M
    Lancet; 1997 Jul; 350(9070):18-22. PubMed ID: 9217715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study.
    Pion SD; Nana-Djeunga H; Niamsi-Emalio Y; Chesnais CB; Deléglise H; Mackenzie C; Stolk W; Fletcher DA; Klion AD; Nutman TB; Boussinesq M; Kamgno J
    Lancet Infect Dis; 2020 Jan; 20(1):102-109. PubMed ID: 31676244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections.
    Turner HC; Walker M; Churcher TS; Basáñez MG
    Parasit Vectors; 2014 May; 7():241. PubMed ID: 24886747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of the microfilarial reservoir of Loa loa in the human host and its implications for monitoring the progr,ammes of Community-Directed Treatment with Ivermectin carried out in Africa.
    Pion DS; Gardon J; Kamgno J; Gardon-Wendel N; Chippaux JP; Boussinesq M
    Parasitology; 2004 Nov; 129(Pt 5):613-26. PubMed ID: 15552406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With
    Zhan B; Bottazzi ME; Hotez PJ; Lustigman S
    Front Cell Infect Microbiol; 2022; 12():869039. PubMed ID: 35444961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Can Onchocerciasis Elimination in Africa Be Accelerated? Modeling the Impact of Increased Ivermectin Treatment Frequency and Complementary Vector Control.
    Verver S; Walker M; Kim YE; Fobi G; Tekle AH; Zouré HGM; Wanji S; Boakye DA; Kuesel AC; de Vlas SJ; Boussinesq M; Basáñez MG; Stolk WA
    Clin Infect Dis; 2018 Jun; 66(suppl_4):S267-S274. PubMed ID: 29860291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control.
    Tekle AH; Elhassan E; Isiyaku S; Amazigo UV; Bush S; Noma M; Cousens S; Abiose A; Remme JH
    Parasit Vectors; 2012 Feb; 5():28. PubMed ID: 22313631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
    Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
    Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of Onchocerciasis Elimination Using a "Test-and-not-treat" Strategy in Loa loa Co-endemic Areas.
    Blok DJ; Kamgno J; Pion SD; Nana-Djeunga HC; Niamsi-Emalio Y; Chesnais CB; Mackenzie CD; Klion AD; Fletcher DA; Nutman TB; de Vlas SJ; Boussinesq M; Stolk WA
    Clin Infect Dis; 2021 Jun; 72(12):e1047-e1055. PubMed ID: 33289025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of test-and-treat with doxycycline and temephos ground larviciding as alternative strategies for accelerating onchocerciasis elimination in an area of loiasis co-endemicity: the COUNTDOWN consortium multi-disciplinary study protocol.
    Wanji S; Nji TM; Hamill L; Dean L; Ozano K; Njouendou AJ; Abong RA; Obie ED; Amuam A; Ekanya R; Ndongmo WPC; Ndzeshang BL; Fung EG; Nnamdi DB; Nkimbeng DA; Teghen S; Kah E; Piotrowski H; Forrer A; Khan JAM; Woode ME; Niessen L; Watson V; Njoumemi Z; Murdoch ME; Thomson R; Theobald S; Enyong P; Turner JD; Taylor MJ
    Parasit Vectors; 2019 Dec; 12(1):574. PubMed ID: 31801631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of ivermectin on onchocerciasis in villages co-endemic for lymphatic filariasis in an area of onchocerciasis recrudescence in Burkina Faso.
    Nikièma AS; Koala L; Sondo AK; Post RJ; Paré AB; Kafando CM; Kambiré RS; Sow B; Bougouma C; Dabiré RK; Traoré S
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009117. PubMed ID: 33647010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination?
    Hamley JID; Blok DJ; Walker M; Milton P; Hopkins AD; Hamill LC; Downs P; de Vlas SJ; Stolk WA; Basáñez MG
    Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):269-280. PubMed ID: 33515042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative treatment strategies to accelerate the elimination of onchocerciasis.
    Boussinesq M; Fobi G; Kuesel AC
    Int Health; 2018 Mar; 10(suppl_1):i40-i48. PubMed ID: 29471342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onchocerca volvulus infection in Tihama region - west of Yemen: Continuing transmission in ivermectin-targeted endemic foci and unveiled endemicity in districts with previously unknown status.
    Mahdy MAK; Abdul-Ghani R; Abdulrahman TAA; Al-Eryani SMA; Al-Mekhlafi AM; Alhaidari SAA; Azazy AA
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006329. PubMed ID: 29505580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-endemicity of loiasis and onchocerciasis in rain forest communities in southwestern Nigeria.
    Ojurongbe O; Akindele AA; Adeleke MA; Oyedeji MO; Adedokun SA; Ojo JF; Akinleye CA; Bolaji OS; Adefioye OA; Adeyeba OA
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003633. PubMed ID: 25812086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term impact of large scale community-directed delivery of doxycycline for the treatment of onchocerciasis.
    Tamarozzi F; Tendongfor N; Enyong PA; Esum M; Faragher B; Wanji S; Taylor MJ
    Parasit Vectors; 2012 Mar; 5():53. PubMed ID: 22433114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vector control and entomological capacity for onchocerciasis elimination.
    Tirados I; Thomsen E; Worrall E; Koala L; Melachio TT; Basáñez MG
    Trends Parasitol; 2022 Jul; 38(7):591-604. PubMed ID: 35379556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Test-and-Not-Treat Strategy for Onchocerciasis in Loa loa-Endemic Areas.
    Kamgno J; Pion SD; Chesnais CB; Bakalar MH; D'Ambrosio MV; Mackenzie CD; Nana-Djeunga HC; Gounoue-Kamkumo R; Njitchouang GR; Nwane P; Tchatchueng-Mbouga JB; Wanji S; Stolk WA; Fletcher DA; Klion AD; Nutman TB; Boussinesq M
    N Engl J Med; 2017 Nov; 377(21):2044-2052. PubMed ID: 29116890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.